13,049 Medtronic PLC $MDT Shares Acquired by Kimelman & Baird LLC

Posted by Brian Himes on Nov 8th, 2026

Kimelman & Baird LLC raised its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 8.0% during the third quarter, HoldingsChannel reports. The firm owned 176,720 shares of the medical technology company’s stock after purchasing an additional 13,049 shares during the period. Kimelman & Baird LLC’s holdings in Medtronic were worth $15,249,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Genesis Private Wealth LLC lifted its position in shares of Medtronic by 2.0% in the 3rd quarter. Genesis Private Wealth LLC now owns 5,170 shares of the medical technology company’s stock worth $446,000 after purchasing an additional 103 shares during the period. LightSquare Wealth Management LLC boosted its stake in shares of Medtronic by 3.6% during the third quarter. LightSquare Wealth Management LLC now owns 2,932 shares of the medical technology company’s stock valued at $253,000 after purchasing an additional 103 shares in the last quarter. Kennebec Savings Bank increased its holdings in Medtronic by 1.2% during the third quarter. Kennebec Savings Bank now owns 9,201 shares of the medical technology company’s stock valued at $794,000 after buying an additional 110 shares during the period. Petredis Investment Advisors LLC increased its holdings in Medtronic by 0.4% during the third quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company’s stock valued at $2,275,000 after buying an additional 114 shares during the period. Finally, Aviance Capital Partners LLC increased its holdings in Medtronic by 2.1% during the third quarter. Aviance Capital Partners LLC now owns 5,469 shares of the medical technology company’s stock valued at $472,000 after buying an additional 114 shares during the period. Institutional investors own 82.06% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares of the company’s stock, valued at approximately $10,167,936. This represents a 8.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 2nd. Barclays raised Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $92.00 price target on shares of Medtronic in a report on Thursday, September 3rd. Mizuho set a $115.00 price target on Medtronic in a research report on Wednesday, September 2nd. Finally, BTIG Research decreased their price objective on Medtronic from $100.00 to $99.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Eighteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average target price of $102.88.

Read Our Latest Stock Report on MDT

Medtronic Stock Down 2.9%

NYSE:MDT opened at $101.82 on Friday. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The stock has a market capitalization of $130.24 billion, a P/E ratio of 25.08, a P/E/G ratio of 2.38 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The company’s 50-day simple moving average is $92.70 and its 200-day simple moving average is $88.45.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Medtronic Company Profile

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products.

The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Medtronic is headquartered in Dublin, Ireland, and maintains significant operations in Minnesota, where the company was founded.